Jump to navigation Jump to search
- crizotinib (also a ROS1 inhibitor) approved in Aug 2011 by the US FDA for ALK-positive NSCLC.
- ceritinib, approved by the FDA in April 2014 for treatment of NSCLC.
- alectinib FDA approved Dec 2015 (accelerated), full approval in 2017 for ALK-positive NSCLC.
- brigatinib (also an EGFR inhibitor) approved in April 2017 by the US FDA for ALK-positive NSCLC.
- lorlatinib approved in 2018 by the US FDA for ALK-positive NSCLC.
This section needs to be updated.February 2016)(
Additional ALK inhibitors currently (or soon to be) undergoing clinical trials include:
- Entrectinib (Nerviano's NMS-E628, licensed by Ignyta and renamed RXDX-101, in the U.S. orphan drug designation and rare pediatric disease designation for the treatment of neuroblastoma and orphan drug designation for treatment of TrkA-, TrkB-, TrkC-, ROS1- and ALK-positive NSCLC)
- Lorlatinib (PF-06463922, Pfizer)
- TSR-011 (Tesaro)
- CEP-37440 (Teva)
- X-396 (Xcovery)
- Nelsen (2010). "ALK Inhibitors: Possible New Treatment for Lung Cancer".
- Farmer (2010). "Non-Small-Cell Lung Cancer Standards of Care Challenged by a Cornucopia of New Drugs".
- Chustecka (2010). "Crizotinib in ALK-NSCLC; Response Rate "Unprecedented"".
- "FDA Approves Ceritinib for ALK-Positive Lung Cancer". Medscape. April 29, 2014.
- Galkin; et al. (2007). "Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK".
- "Archived copy". Archived from the original on 2010-12-23. Retrieved 2010-10-02.CS1 maint: Archived copy as title (link)